Silvant Capital Management’s Idexx Laboratories IDXX Stock Holding History

Silvant Capital Management’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$7.44M	Buy	13,248 +213	+2%	+$137K	0.26%	43
2025 Q4	$8.82M	Buy	13,035 +1,918	+17%	+$1.31M	0.3%	42
2025 Q3	$7.1M	Sell	11,117 -1,051	-9%	-$638K	0.25%	49
2025 Q2	$6.53M	Hold	12,168	–	–	0.25%	54
2025 Q1	$5.11M	Hold	12,168	–	–	0.24%	58
2024 Q4	$5.03M	Hold	12,168	–	–	0.21%	61
2024 Q3	$6.15M	Hold	12,168	–	–	0.27%	49
2024 Q2	$5.93M	Sell	12,168 -3,361	-22%	-$1.69M	0.26%	56
2024 Q1	$8.38M	Hold	15,529	–	–	0.4%	37
2023 Q4	$8.62M	Hold	15,529	–	–	0.46%	33
2023 Q3	$6.79M	Hold	15,529	–	–	0.41%	39
2023 Q2	$7.8M	Hold	15,529	–	–	0.44%	36
2023 Q1	$7.77M	Hold	15,529	–	–	0.51%	36
2022 Q4	$6.34M	Sell	15,529 -161	-1%	-$62.5K	0.45%	42
2022 Q3	$5.11M	Buy	+15,690	New	+$5.76M	0.35%	51

Other funds holding IDXX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Silvant Capital Management's IDXX Position: Q1 2026 in Review

Silvant Capital Management increased its Idexx Laboratories (IDXX) stake by 1.6% in Q1 2026, buying an estimated $137K and bringing the position to 13,248 shares worth $7.44M. The position accounts for 0.26% of the portfolio, ranked #43.

Silvant Capital Management first reported a position in IDXX in Q3 2022 and has held it in 15 quarters since. The position peaked at $8.82M in Q4 2025. 1,311 funds tracked by Wall St. Rank hold IDXX as of Q1 2026.

Silvant Capital Management held 13,248 shares of Idexx Laboratories worth $7.44M as of Q1 2026.
Silvant Capital Management bought 213 Idexx Laboratories shares in Q1 2026, an estimated $137K.
Idexx Laboratories made up 0.26% of Silvant Capital Management's portfolio in Q1 2026, its #43 holding.
Silvant Capital Management first reported a position in Idexx Laboratories in Q3 2022 and has held it in 15 quarters since.
Silvant Capital Management's Idexx Laboratories position peaked at $8.82M in Q4 2025.
1,311 funds tracked by Wall St. Rank held Idexx Laboratories as of Q1 2026.

Based on Silvant Capital Management's 13F filing for Q1 2026, filed 14 May 2026.